US 12054492
Imidazole-containing inhibitors of ALK2 kinase
granted A61PA61P19/00A61P35/00
Quick answer
US patent 12054492 (Imidazole-containing inhibitors of ALK2 kinase) held by BioCryst Pharmaceuticals, Inc. expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 37
- CPC classes
- A61P, A61P19/00, A61P35/00